Ontology highlight
ABSTRACT:
SUBMITTER: Bachanova V
PROVIDER: S-EPMC6055922 | biostudies-literature | 2018 Mar
REPOSITORIES: biostudies-literature
Bachanova Veronika V Sarhan Dhifaf D DeFor Todd E TE Cooley Sarah S Panoskaltsis-Mortari Angela A Blazar Bruce R BR Curtsinger Julie M JM Burns Linda L Weisdorf Daniel J DJ Miller Jeffrey S JS
Cancer immunology, immunotherapy : CII 20171207 3
We report a novel phase 2 clinical trial in patients with poor prognosis refractory non-Hodgkin lymphoma (NHL) testing the efficacy of haploidentical donor natural killer (NK) cell therapy (NK dose 0.5-3.27 × 10<sup>7</sup> NK cells/kg) with rituximab and IL-2 (clinicaltrials.gov NCT01181258). Therapy was tolerated without graft-versus-host disease, cytokine release syndrome, or neurotoxicity. Of 14 evaluable patients, 4 had objective responses (29%; 95% CI 12-55%) at 2 months: 2 had complete re ...[more]